Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis
- 36 Downloads
The new QuantiFERON-TB Gold Plus employs modified peptides optimized to elicit an IFNγ response from CD8+ cytotoxic T lymphocytes in addition to CD4+ T cells. With a view to improve the difficult identification of TB cases, we assessed the combination of two specific immunological markers comprising IFNγ secretion and T cells co-expression of CD25 and CD134 in response to Mycobacterium tuberculosis-specific antigens. A total of 34 subjects with suspected TB and 10 age-matched HD were prospectively enrolled. Assessing the performance of QFT-Plus in terms of the TB1 and TB2 results, we found that in TB patients, the quantitative IFNγ value in TB2 was similar to that in TB1, and we did not find any differences irrespective of the disease (pulmonary or extra-pulmonary). The flow cytometric CD25/CD134 assay, allowed a more accurate differentiation between M. tuberculosis-infected and uninfected patients, with a better combination of sensitivity and specificity, especially by evaluation of CD4+ T-cell subset. All individuals with negative QFT-Plus results displayed a positive CD25/CD134 response. Overall, a positive correlation was found between T cells co-expressing CD25/CD134 and IFNγ levels in response to both QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes. We demonstrated that both TB1 and TB2 induce a higher expression of CD25+CD134+ markers on CD4+ T cells among infected TB subjects, compared to the lower degree of CD8+ T cells, mainly induced to TB2 stimulation. We suggest that a combined use of classic QFT-Plus and specific CD25/CD134 response may be a useful means in the diagnostic workup for active TB.
KeywordsQFT-Plus Tuberculosis Flow cytometry CD25/CD134
The authors gratefully acknowledge Qiagen for providing the QFT-Plus kits, and they acknowledge Parni Nijhawan for editing the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.WHO (2017) Global Tuberculosis Report 2017. World Health Organization, Geneva. http://www.who.int/tb/publications/global_report/en/. Accessed 3 July 2017
- 7.QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA Package Insert. QUIAGEN http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf. Accessed 7 Oct 2017
- 13.Kim K, Perera R, Tan DBA, Fernandez S, Seddiki N, Waring, French MA (2014) Circulating mycobacterial-reactive CD4 + T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Tuberculosis 94:450–494Google Scholar
- 16.Hoffmann H, Avsar K, Gores R, Mavi SC, Hofmann-Thiel S (2016) Equal sensitivity of the new generation QuantiFERON-TB Gold Plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 22:701–703. https://doi.org/10.1016/j.cmi.2016.05.006. (Epub 2016 May 13)CrossRefGoogle Scholar
- 19.Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M et al (2018) Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. J Infect Chemother 24:188 – 192. https://doi.org/10.1016/j.jiac.2017.10.009 CrossRefGoogle Scholar
- 20.Theel ES, Hilgart H, Breen-Lyles M, McCoy K, Flury R, Breeher LE et al (2018) Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers. J Clin Microbiol 56:e00614–e00618. https://doi.org/10.1128/JCM.00614-18 Google Scholar
- 23.Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G et al (2001) Direct ex vivo analysis of antigen specific IFN-gamma—secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 167:5217–5225CrossRefGoogle Scholar
- 30.Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M et al (2013) Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol 43:1568–1577. https://doi.org/10.1002/eji.201243262 CrossRefGoogle Scholar
- 42.Sauzullo I, Scrivo R, Sessa P, Mengoni F, Vullo V, Valesini G, Mastroianni CM (2018) Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. Sci Rep 8:7881. https://doi.org/10.1038/s41598-018-26097-x CrossRefGoogle Scholar